Chiral Interaction Is a Decisive Factor To Replace d-DNA with l-DNA Aptamers-Reference-Cited by-同舟云学术

Chiral Interaction Is a Decisive Factor To Replace d-DNA with l-DNA Aptamers

Published:2020-04-06 Issue:9 Volume:92 Page:6470-6477
ISSN:0003-2700
Container-title:Analytical Chemistry
language:en
Short-container-title:Anal. Chem.

Author:

Feng Xue-Nan¹,Cui Yun-Xi¹^ORCID,Zhang Jing¹,Tang An-Na¹^ORCID,Mao Han-Bin²^ORCID,Kong De-Ming¹^ORCID

Affiliation:

1. State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, Nankai University, Tianjin 300071, P. R. China

2. Department of Chemistry & Biochemistry, Kent State University, Kent, Ohio 44242, United States

Funder

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Analytical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.analchem.9b05676

Reference56 articles.

1. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA

2. In vitro selection of RNA molecules that bind specific ligands

3. Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase

4. Structures of riboswitch RNA reaction states by mix-and-inject XFEL serial crystallography

5. The interaction landscape between transcription factors and the nucleosome

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirror-Image DNA Nanobox for Enhancing Environment Resistance of Nucleic Acid Probes;ACS Nano;2024-08-15

2. Selection of Fluorinated Aptamer Targeting RNA Element with Different Chirality;2024-06-27

3. Aptamer‐functionalized field‐effect transistor biosensors for disease diagnosis and environmental monitoring;Exploration;2023-05-11

4. Chiral Reagent- and Separation-Free Determination of Homocysteine Enantiomers Based on Molecular Cluster-Guided Morphological Evolution of Silver Nanotriangles;2023

5. Functional Zeolitic Imidazolate Framework for Robust l ‐Deoxyribozyme‐Based Therapy;Small;2022-10-10